An observational study in Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps, sponsored by The European Forum for Research and Education in Allergy and Airway Diseases. Recruiting at 32 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by The European Forum for Research and Education in Allergy and Airway Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Nasal Polyps with a site in Spain — 4 open to participants now, 7 under way, 3 of them phase 3. Nasal Polyps · Spain.
Among the 22 studies in Nasal Polyps with a site in Spain, this one is one of 4 that started in 2024, is one of 4 observational ones, and was the 21st registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →4 of the 22 studies in Nasal Polyps with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain
Ages 18–80 · Healthy volunteers
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 18–80
Eli Lilly and Company · Sites in Spain, United States, Argentina and 17 more countries
Ages 12+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 1,000 is above the median of 100 across 47 observational studies indexed under Nasal Polyps.
Median enrollment 178 across the 18 interventional studies, 637 across the 4 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with The European Forum for Research and Education in Allergy and Airway Diseases as lead sponsor.
The European Forum for Research and Education in Allergy and Airway Diseases has 1 study filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
4 of the studies in Nasal Polyps with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07814924Instituto de Investigación Marqués de ValdecillaMepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). | 2026-12-31 |
| NCT05923047Instituto de Investigación Marqués de ValdecillaMepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. | 2027-01-01 |
| NCT06970977The European Forum for Research and Education in Allergy and Airway DiseasesCRS Questionnaire Validation Project | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Nasal Polyps with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The 'CRS validation project' consists of a joint effort of 32 medical centers in Europe, the USA, and South Africa to carry out the validation of 2 novel questionnaires designated to measure self-perceived severity and control of Chronic Rhinosinusitis (with or without nasal polyps).
This study will validate translated versions of the same set of questionnaires simultaneously in the centers involved after recruiting a total of 1000 patients, while data collection, statistical analysis, and creation of the study report will be carried out by the statistical department of the University of Leuven.
Patients will be recruited from the regular ENT practice of their hospital to minimize the complexity of the study.
The objectives of this study are as follows:
Adult patients, capable of giving consent, with certified CRS and no recent sinus surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Validation of a new questionnaire
Validation of a questionnaire based on similar questionnaires already approved for use in other airway diseases. The aim to measure the current perceived status of a patient with chronic rhinosinusitis in terms of control and severity. A new questionnaire will be tested and compared with current tools. For this purpose, a set of questionnaires has been developed including the EPOS criteria for chronic rhinosinusitis, the SNOT-22, the patient global assessment tool and the VAS scores, among others. All these questionnaires will be completed by the patient at visit 1 and the results will be analysed once the recruitment target of 1,000 patients has been reached. No second patient participation is required.
Time frame: Through study completion, an average of 6 months
Evaluation of the results
Evaluation of the results of this questionnaire in comparison with other tools currently available. Once the target of recruiting 1000 patients has been reached, the results will be statistically analysed. Parallels will be drawn between the responses obtained by the usual means and those captured in the questionnaires to be validated. It is expected that, in all cases, the degree of control and severity represented in the questionnaires to be validated will conform to the EPOS criteria and to the results of the questionnaires usually used. The results will be compared for each of the new questionnaires in general and separately by language. The ultimate goal is to validate what will become the diagnostic gold standard for chronic rhinosinusitis.
Time frame: Through study completion, an average of 6 months
Validation of a new questionnaire
Validation of a questionnaire based on feedback collected from patients with CRS where they expressed which are the symptoms that most afflict them or are most present, related to their disease. The aim to measure the current perceived status of a patient with chronic rhinosinusitis in terms of control and severity. A new questionnaire will be tested and compared with current tools. For this purpose, a set of questionnaires has been developed including the EPOS criteria for chronic rhinosinusitis, the SNOT-22, the patient global assessment tool and the VAS scores, among others. All these questionnaires will be completed by the patient at visit 1 and the results will be analysed once the recruitment target of 1,000 patients has been reached. No second patient participation is required.
Time frame: Through study completion, an average of 6 months
Evaluation of the results
Evaluation of the results of this questionnaire in comparison with other tools currently available. Once the target of recruiting 1000 patients has been reached, the results will be statistically analysed. Parallels will be drawn between the responses obtained by the usual means and those captured in the questionnaires to be validated. It is expected that, in all cases, the degree of control and severity represented in the questionnaires to be validated will conform to the EPOS criteria and to the results of the questionnaires usually used.
Time frame: Through study completion, an average of 6 months
Started Sep 2024 (actual). Primary completion is estimated for Jun 2027, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.